Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GREGORY T GREENWOOD

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1316946858
CMS profile
241465
Location
WINSTON-SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$74,239.71

144 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GREGORY T GREENWOOD

NPI 1316946858 · CMS profile ID 241465

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

WINSTON-SALEM, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
GREGORY T GREENWOOD, NPI 1316946858, CMS profile ID 241465, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 144 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1316946858?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

144 matching records · $74,239.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 144 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 144.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $2,700.0010/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829468765 CMS
AstraZeneca Pharmaceuticals LP $1,000.0010/11/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829804177 CMS
AstraZeneca Pharmaceuticals LP $15.0010/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829547987 CMS
AstraZeneca Pharmaceuticals LP $22.4010/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829636807 CMS
AstraZeneca Pharmaceuticals LP $192.5010/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829796021 CMS
AstraZeneca Pharmaceuticals LP $107.6010/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829984883 CMS
AstraZeneca Pharmaceuticals LP $1,350.0010/07/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829988671 CMS
AstraZeneca Pharmaceuticals LP $122.0810/07/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829998721 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.1610/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789088215 CMS
AstraZeneca Pharmaceuticals LP $101.4510/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829592923 CMS
AstraZeneca Pharmaceuticals LP $2,000.0010/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829398015 CMS
AstraZeneca Pharmaceuticals LP $15.6709/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829374593 CMS
AstraZeneca Pharmaceuticals LP $45.1409/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829901333 CMS
AstraZeneca Pharmaceuticals LP $125.0009/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829994677 CMS
Alexion Pharmaceuticals, Inc. $15.9109/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783141089 CMS
AstraZeneca Pharmaceuticals LP $650.0009/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829638429 CMS
Vifor Pharma, Inc. $23.5209/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816129863 CMS
GlaxoSmithKline, LLC. $13.8609/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801725391 CMS
Amgen Inc. $22.5709/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826343601 CMS
AstraZeneca Pharmaceuticals LP $2,700.0009/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830093855 CMS
Horizon Therapeutics plc $17.6709/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797137467 CMS
AstraZeneca Pharmaceuticals LP $120.3708/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829604003 CMS
AstraZeneca Pharmaceuticals LP $117.6008/31/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829785955 CMS
GlaxoSmithKline, LLC. $73.3508/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802137089 CMS
Bard Peripheral Vascular, Inc. $16.3708/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 837151875 CMS
AstraZeneca Pharmaceuticals LP $14.8008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830005859 CMS
AstraZeneca Pharmaceuticals LP $650.0008/12/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829678165 CMS
AstraZeneca Pharmaceuticals LP $13.3608/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829703379 CMS
AstraZeneca Pharmaceuticals LP $2,350.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829416455 CMS
AstraZeneca Pharmaceuticals LP $1,350.0008/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830120639 CMS
Horizon Therapeutics plc $19.7608/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797137463 CMS
AstraZeneca Pharmaceuticals LP $650.0008/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830193947 CMS
AstraZeneca Pharmaceuticals LP $650.0008/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829271031 CMS
AstraZeneca Pharmaceuticals LP $132.1408/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829809213 CMS
AstraZeneca Pharmaceuticals LP $66.0808/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829878575 CMS
AstraZeneca Pharmaceuticals LP $23.4508/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830069613 CMS
AstraZeneca Pharmaceuticals LP $126.5608/05/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830104777 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.9408/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789098707 CMS
AstraZeneca Pharmaceuticals LP $2,000.0008/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829894381 CMS
AstraZeneca Pharmaceuticals LP $115.9507/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829552171 CMS
AstraZeneca Pharmaceuticals LP $650.0007/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829561839 CMS
AstraZeneca Pharmaceuticals LP $79.5207/29/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829850809 CMS
Otsuka America Pharmaceutical, Inc. $15.7807/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834733023 CMS
Alexion Pharmaceuticals, Inc. $960.0007/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783141105 CMS
GlaxoSmithKline, LLC. $20.3707/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802995595 CMS
Otsuka America Pharmaceutical, Inc. $1,620.0007/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834733021 CMS
AstraZeneca Pharmaceuticals LP $2,700.0007/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829962023 CMS
Mallinckrodt Hospital Products Inc. $32.5807/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845358149 CMS
Vifor Pharma, Inc. $24.4007/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816118319 CMS
AstraZeneca Pharmaceuticals LP $110.7007/13/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829799917 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $65,351.07 222
PY2020 $65,837.47 148
PY2021 $74,239.71 144
PY2022 $150,141.54 316
PY2023 $166,490.04 311
PY2024 $198,894.93 372
PY2025 $225,635.16 382

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $548.12 6
PY2025 Principal investigator $1,129,847.75 30
PY2024 Recipient $2,000.00 1
PY2024 Principal investigator $392,464.35 18
PY2023 Principal investigator $184,406.29 161
PY2022 Principal investigator $209,906.66 77
PY2021 Principal investigator $411,211.84 135
PY2020 Principal investigator $456,136.17 166
PY2019 Principal investigator $320,420.78 242

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

36 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $61,844.82 12/18/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH
a phase I and IIa randomized,double blind,placebo controlled study to evaluate the safety and pharmacokinetics of AZD7760 in healthy participants and in patients with end stage kidney disease receiving hemodialysis through a central venous catheter No dispute reported 06/30/2026 1185551629
Principal investigator 1 Boehringer Ingelheim International GmbH $27,160.00 12/17/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699468
Principal investigator 1 ABBVIE INC. $1,350.00 12/10/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH ASSOCIATES
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202529876
Principal investigator 1 Boehringer Ingelheim International GmbH $46.88 12/01/2025 Non-covered Recipient Entity
Brookview Hills Research
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220699470
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $20,030.88 11/30/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996680
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 11/19/2025 Non-covered Recipient Entity
Brookview Hills Research
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220699472
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 11/19/2025 Non-covered Recipient Entity
Brookview Hills Research
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220699474
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 11/19/2025 Non-covered Recipient Entity
Brookview Hills Research
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220699476
Principal investigator 1 Boehringer Ingelheim International GmbH $25,015.00 11/17/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699466
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $80,123.52 10/31/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996678
Principal investigator 1 Boehringer Ingelheim International GmbH $19,765.00 10/22/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699464
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 09/30/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996676
Principal investigator 1 Amgen Inc. $27,050.46 09/21/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH ASSOCIATES LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246639803
Principal investigator 1 Boehringer Ingelheim International GmbH $26,315.00 09/08/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699462
Principal investigator 1 ABBVIE INC. $14,964.00 09/04/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH ASSOCIATES
A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) No dispute reported 06/30/2026 1202509098
Principal investigator 1 Boehringer Ingelheim International GmbH $34,340.00 08/18/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699460
Recipient ABBVIE INC. $15.00 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398621
Recipient ABBVIE INC. $52.88 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398624
Recipient ABBVIE INC. $15.00 08/08/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398628
Recipient ABBVIE INC. $234.78 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398606
Recipient ABBVIE INC. $215.46 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398610
Recipient ABBVIE INC. $15.00 08/07/2025 Covered Recipient Physician A Study to Assess Adverse Events and Effectiveness of IntraVenous Infusions of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (ANCHOR) No dispute reported 06/30/2026 1202398617
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 07/31/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996674
Principal investigator 1 Boehringer Ingelheim International GmbH $29,215.00 07/07/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699458
Principal investigator 1 AstraZeneca UK Limited $12,800.00 07/02/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH
Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APPRECIATE) No dispute reported 06/30/2026 1185551631
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $40,061.76 06/30/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996672
Principal investigator 1 Boehringer Ingelheim International GmbH $14,920.00 06/09/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699454
Principal investigator 1 Boehringer Ingelheim International GmbH $23,660.00 05/12/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699456
Principal investigator 1 Boehringer Ingelheim International GmbH $4,905.00 04/09/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699452
Principal investigator 1 Boehringer Ingelheim International GmbH $13,080.00 03/12/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699450
Principal investigator 1 Boehringer Ingelheim International GmbH $13,570.00 02/14/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220699448
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $80,123.52 01/31/2025 Non-covered Recipient Entity
Brookview Hills Research
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220996670
Principal investigator 1 Amgen Inc. $330,276.54 01/27/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH ASSOCIATES LLC
A Randomized, Double-blind, Placebo-controlled Phase 4 Clinical Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Participants With Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis No dispute reported 06/30/2026 1246639805
Principal investigator 1 AstraZeneca Pharmaceuticals LP $144,416.70 01/24/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185551625
Principal investigator 1 AstraZeneca Pharmaceuticals LP $600.00 01/24/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH
The purpose of the D4325C00007 study is to identify and characterise patients with known or newly diagnosed CKD for possible participation in future renal clinical studies and to obtain an overview on current treatment choices for this patient group in different regions No dispute reported 06/30/2026 1185551627
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,835.51 01/10/2025 Non-covered Recipient Entity
BROOKVIEW HILLS RESEARCH
TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal No dispute reported 06/30/2026 1185551623